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Abstract
Background: Survival after diagnosis is a fundamental concern in cancer epidemiology. In resource-rich settings,
ambient clinical databases, municipal data and cancer registries make survival estimation in real-world populations
relatively straightforward. In resource-poor settings, given the deficiencies in a variety of health-related data systems, it
is less clear how well we can determine cancer survival from ambient data.
Methods: We addressed this issue in sub-Saharan Africa for Kaposi’s sarcoma (KS), a cancer for which incidence has
exploded with the HIV epidemic but for which survival in the region may be changing with the recent advent of
antiretroviral therapy (ART). From 33 primary care HIV Clinics in Kenya, Uganda, Malawi, Nigeria and Cameroon
participating in the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortia in 2009–2012, we
identified 1328 adults with newly diagnosed KS. Patients were evaluated from KS diagnosis until death, transfer to
another facility or database closure.
Results: Nominally, 22 % of patients were estimated to be dead by 2 years, but this estimate was clouded by
45 % cumulative lost to follow-up with unknown vital status by 2 years. After adjustment for site and CD4 count,
age <30 years and male sex were independently associated with becoming lost.
Conclusions: In this community-based sample of patients diagnosed with KS in sub-Saharan Africa, almost half
became lost to follow-up by 2 years. This precluded accurate estimation of survival. Until we either generally
strengthen data systems or implement cancer-specific enhancements (e.g., tracking of the lost) in the region,
insights from cancer epidemiology will be limited.
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Background
Survival after diagnosis is one of the most fundamental
parameters in cancer epidemiology. Survival encompasses
both the natural biologic history of a malignancy as well
as the effects of therapeutic interventions. Monitoring sur-
vival over time, for example, can be a powerful tool to
measure the cumulative impact of medical advancements.
In resource-rich settings, ambient clinical systems diag-
nose cancers as they occur in the community, municipal
registries record all deaths, and well-established cancer
registries and epidemiologic platforms (such as the Sur-
veillance, Epidemiology and End Results (SEER) program
in the U.S. [1]) combine and synthesize data to make can-
cer survival estimation in real-world populations accurate
and straightforward. In resource-poor settings, the im-
portance of cancer has recently drawn attention [2–4],
but, given the deficiencies in healthcare information sys-
tems in these regions, it is less clear how well we can de-
termine cancer survival with ambient data.
Kaposi’s sarcoma (KS) in sub-Saharan Africa is an
example of a malignancy in a resource-limited setting
which would benefit from knowledge about current
survival. KS was among the more common cancers in
Africa even before HIV [5, 6], exploded in incidence in
the HIV era [7–9], and exhibited poor survival early on
in the HIV epidemic [8, 10]. More recently, antiretroviral
therapy (ART) has substantially improved KS survival in
resource-replete settings [11–13] and is now becoming
more widely available in resource-poor settings [14].
However, the finding of improved survival in the ART
era in resource-rich settings, such as the U.S., cannot
automatically be extrapolated to resource-poor settings,
such as Africa. Important differences in availability of
oncologic care [15], co-morbidities [16], as well as differ-
ences in human host and viral etiologic pathogen [17]
suggest that we must examine KS survival directly in sub-
Saharan Africa [18–21] if we hope to understand the im-
pact of the ART era.
To address whether ambient data can answer a funda-
mental question of cancer survival in sub-Saharan Africa,
we examined the feasibility of estimating survival after a
KS diagnosis in the current era of burgeoning ART use.
We took advantage of an epidemiologic network of
clinical data from throughout sub Saharan Africa [22]
to identify a large community-representative sample of
KS cases in five countries. We then combined these
clinical data with all other available administrative data
to attempt to estimate survival after KS diagnosis.
Methods
Design and study population
Among HIV-infected adults diagnosed with KS, we per-
formed a cohort analysis of time to death using ambi-
ent clinical and administrative data. We retrospectively
identified a consecutive sample of HIV-infected adults
(≥18 years old) diagnosed with KS from January 2009
to July 2012 who were receiving their primary care at
one of thirty-three HIV clinics in Kenya, Uganda, Malawi,
Nigeria and Cameroon. The sites included 26 clinics in a
network in western Kenya (Academic Model Providing
Access to Healthcare (AMPATH)), one clinic in Uganda
(Immune Suppression Syndrome Clinic (ISS) in Mbarara),
two clinics in Nigeria (University of Abuja Teaching
Hospital and National Hospital of Abuja), three clinics in
Cameroon (Limbe Regional Hospital, General Hospital of
Yaoundé and Military Hospital of Yaoundé), and one clinic
from Malawi (Lighthouse Trust in Lilongwe). Each site
administers ART in accordance with their national guide-
lines, and each participates in the International Epidemio-
logic Databases to Evaluate AIDS (IeDEA) Consortium,
which, in Africa, consists of East, West, Central and
Southern Africa regions [22]. IeDEA was established in
2005 to harmonize diverse HIV/AIDS-related data col-
lected as part of routine clinical care in seven regions
throughout the world [23]. All patients provided written
consent for data derived from their care at the participat-
ing clinic sites to be used for purposes of research through
IeDEA. No children were involved in this study. Ethics
committees that approved this study are listed in the
Funding section of this paper.
Measurements
At the participating clinics, KS diagnosis was made dur-
ing the course of routine clinical care, either by clinical
examination alone or with biopsy confirmation. Both in-
dividuals who were diagnosed at their initial clinic visit
and during the course of their care were included. As-
certainment of death was through review of clinic charts,
clinic databases and municipal death registries, where
available. Clinics are informed of a patient’s death in a
variety of ways, including from reports from adjacent
hospital units or from family members. All of the par-
ticipating clinics had some form of a tracking program
in place to follow-up on lost patients. Demographic char-
acteristics, including age and sex, were routinely collected
by the clinics and extracted from the respective clinic
databases. CD4+ T cell counts were performed at clinical
laboratories associated with each of the clinics. The
CD4 count proximal to KS diagnosis, when available,
was defined as CD4 count closest to date of diagnosis,
within 180 days prior to KS diagnosis or up to 14 days
after.
Statistical analysis
Time zero for the analysis was date of KS diagnosis.
Patients were followed until death, and for those not
known to be dead, the last known date known to be alive
either from a clinic visit or transfer to another facility.
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Cumulative survival following KS diagnosis was estimated
via the Kaplan-Meier technique, with censoring at transfer
or last clinic visit. This approach assumes that the rate of
death among those lost to follow-up is the same as those
whose disposition is known. Loss to follow-up was defined
as absence from clinic during the 3 months prior to
database closure with no evidence of death or transfer.
Incidence of loss to follow-up was calculated using the
Aalen-Johansen estimator with death as a competing
event [24, 25]. Proportional hazards regression was
used to evaluate the independent association between
various exposures measured at the time of KS diagnosis
(age, sex and proximal CD4 count) and loss to follow-up.
For the regression analysis, missing exposure variables
were accommodated for with multiple imputation, with
ten copies, performed with the “mi impute” command in
Stata version 12.1 (Stata Corp., College Station, Texas)
[26, 27]. Standard errors were calculated using Rubin’s
rules, which account for the variability in results between
the imputed datasets [27].
Results
Across the 33 HIV clinics, we analyzed data from 1328
adults diagnosed with KS during the course of primary
care for HIV disease in all four African regions in the
IeDEA Consortium. There were 677 cases from Kenya,
172 from Uganda, 57 from Nigeria, 67 from Cameroon
and 355 from Malawi. Overall, 40 % were women, the
median age was 35 years (interquartile range (IQR): 30–41),
and the median proximal CD4 +T cell count was 159/mm3
(IQR: 59–299) at time of KS diagnosis (Table 1). Most of
the KS diagnoses (72 %) were made on clinical grounds
alone without biopsy.
Patients were followed for a median of 8.9 months
(IQR: 4.0–20) and a collective 1473 person-years in
which 191 patients died. Cumulative mortality, as estimated
by the Kaplan-Meier technique, was 13 % at 6 months
following KS diagnosis, 18 % at 1 year, and 22 % at 2 years.
These estimates of mortality were clouded, however, by a
cumulative loss to follow-up of 23 % (95 % confidence
interval (CI): 21–26 %) at 6 months, 36 % (95 % CI: 33–
38 %) at 1 year, and 45 % (95 % CI: 42–48 %) at 2 years
(Fig. 1). This cumulative loss to follow-up takes death into
account as a competing event. At no site was there an ac-
cessible municipal death registry or any other administra-
tive source in which to search for deaths among those
deemed to be lost.
Given the high frequency of lost to follow-up, we also
explored its determinants. After adjustment for geographic
site in proportional hazards regression, age <30 years
(hazard ratio (HR) 1.41, 95 % CI: 1.11–1.79) and male
sex (HR 1.35, 95 % CI: 1.12–1.63) were independently
associated with loss to follow-up (Table 2). Those with
CD4 count ≤50 cells/mm3 also had a higher incidence
of becoming lost (HR 1.23, 95 % CI: 0.90–1.67, p = 0.19), al-
though this did not meet conventional levels of statistical
significance. When the analysis was restricted to those with
biopsy-proven KS (n = 378), the results were largely un-
changed, with the exception that CD4 count ≤50 cells/mm3
was significantly associated with loss to follow-up (HR 2.35,
95 % CI: 1.29–4.27, p < 0.01).
Discussion
When attempting to estimate survival in a large HIV pri-
mary care-based sample of patients diagnosed with KS
spanning five countries in sub-Saharan Africa, we found
that almost half were lost to follow-up by the end of
2 years. Because the fraction of those lost is so large and
the disposition of the lost is unknown, it was therefore not
possible to estimate with any certainty a fundamental
parameter in cancer epidemiology — survival — using
data from available clinical and administrative systems. As
Table 1 Characteristics of HIV-infected patients diagnosed with Kaposi’s sarcoma between 2009–2012 in Kenya, Uganda, Nigeria,
Cameroon and Malawi
AMPATH Kenya
(n = 677)
ISS Uganda
(n = 172)
UATH and NHA Nigeria
(n = 57)
Yaounde and Limbe Cameroon
(n = 67)
Lighthouse Malawi
(n = 355)
Total
(n = 1328)
Male sex, %a 60 % 60 % 49 % 49 % 72 % 60 %
Age, yearsa 35 (30–42)b 33 (28–40) 36 (30–41) 35 (30–41) 34 (30–40) 35 (30–41)
CD4+ T cell count/μlc
≤ 50 25 % 24 % 33 % 17 % 11 % 23 %
51-200 32 % 31 % 17 % 50 % 46 % 35 %
201-350 21 % 28 % 39 % 21 % 30 % 24 %
> 350 21 % 16 % 11 % 12 % 13 % 18 %
AMPATH denotes Academic Model Providing Access to Healthcare, ISS denotes Immune Suppression Syndrome Clinic, UATH denotes University of Abuja Teaching
Hospital, NHA denotes National Hospital of Abuja
atwo missing values for sex, four missing values for age
bmedian (interquartile range)
cCD4+ T cell count proximal to KS diagnosis, defined as closest CD4 count to date of KS diagnosis within the period 180 days prior to diagnosis to 14 days after
diagnosis. CD4 data is missing in 33 % of patients. Data presented represent observed (not imputed) values only
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noted earlier, for a technique like the Kaplan-Meier me-
thod to yield an estimate of survival in the face of loss to
follow-up, it requires an assumption that those who are
lost to follow-up have the same outcomes as those who
remain under observation. Since this “non-informative
censoring” assumption is likely implausible in our context
given that a higher portion of the lost patients may in fact
have died [28], our Kaplan-Meier estimate of survival is
essentially uninterpretable.
The substantial loss to follow-up that we observed is
consistent with findings from other cancers in sub-Saharan
Africa [29, 30], as well as KS specifically. Although the
methodologic approaches and metrics vary, reported loss
to follow-up for KS at 1 year or less after diagnosis in
Africa has ranged from 15 to 23 % [18, 19, 21] and was
26 % at 2 years in another report [20]. Our work, which
found an even higher incidence of lost to follow-up,
bolsters these earlier findings in several ways. First, the
IeDEA consortium is a large and diverse population,
which for this project included patients from East,
West, Central and Southern Africa, thus enhancing the
generalizability of the findings. Second, the patients
were not selected from oncology clinics, clinical trials,
registries or a tightly monitored research cohort. Instead,
Fig. 1 Cumulative incidence of loss to follow-up in HIV-infected patients following diagnosis with Kaposi’s sarcoma in five countries in
sub-Saharan Africa
Table 2 Unadjusted and adjusted proportional hazards regression evaluating factors associated with loss to follow-up among
HIV-infected patients with Kaposi’s sarcoma from Kenya, Uganda, Nigeria, Cameroon and Malawi
Characteristic Unadjusted Adjusteda
Hazard Ratio (95 % CI) P value Hazard Ratio (95 % CI) P value
Age, years
≥ 40 Reference Reference
35–39 1.00 (0.78–1.29) 0.96 1.06 (0.82–1.36) 0.69
30–34 1.01 (0.80–1.28) 0.93 1.09 (0.85–1.38) 0.50
< 30 1.30 (1.03–1.64) 0.03 1.41 (1.11–1.79) 0.005
Sex
Female Reference Reference
Male 1.08 (0.91–1.30) 0.38 1.35 (1.12–1.63) 0.002
CD4+ T cells, count/μl
> 350 Reference Reference
201–350 1.00 (0.74–1.35) 0.99 1.03 (0.75–1.42) 0.84
51–200 1.10 (0.82–1.49) 0.52 1.14 (0.84–1.54) 0.24
≤ 50 1.25 (0.92–1.68) 0.15 1.23 (0.90–1.67) 0.19
aadjusted for geographic clinic site (country), age, sex and CD4+ T cell count
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they were — by design — identified at the time of their
initial diagnosis in real-world community-based HIV pri-
mary care settings and their subsequent observation was
entirely without research influence. Indeed, because we
identified patients directly from HIV primary care clinics,
irrespective of whether they had a confirmatory biopsy,
our population is likely different than many registry-based
cancer populations which primarily identify KS diagnoses
from pathology laboratories. Since we do not know which
types of patients with KS in Africa obtain a biopsy diagno-
sis (e.g., they may have more severe disease, or higher so-
cioeconomic status), it is unclear if patients who receive
biopsies are representative of the larger population of all
incident KS. Therefore, if the target is to encompass all
new KS diagnoses in Africa, we believe that our estimate
of the incidence of loss to follow-up among persons with
KS is among the least biased to date.
We were unable to determine survival due to the high
loss to follow-up and the unknown disposition of those
that are lost to follow-up. In prior work from East Africa
that assessed a consecutive sample of HIV-infected
adults attending HIV clinics (including two clinics par-
ticipating in this project), we actively sought after those
who were lost by searching for them in the community
[31]. We found that three possible outcomes occur in
considerable proportions: death, previously undocumented
transfer to another facility, or alive but discontinued care
[32, 33]. Specifically, in this prior work, the cumulative in-
cidence of mortality at 1 year among those that were lost
was ultimately found to be 36 %, once the patients had
been tracked [32, 33]. Such vital status estimates, derived
from a general HIV cohort, are useful but cannot be relied
upon to accurately estimate mortality rates in selected sub-
populations such as patients with KS. Likewise, it is not
likely that nomogram approaches to correct survival in the
face of lost to follow-up that were developed for all HIV-
infected patients on ART (irrespective of KS) [34] will per-
form adequately amongst patients with KS. Work from
South Africa demonstrates that loss to follow-up is higher
in KS patients compared to other HIV-infected patients
starting on ART [21]. We speculate that this is because a
larger fraction of patients with KS die, their deaths go
unrecognized by their primary care clinics, and, hence,
they are deemed lost to follow-up. Indeed, the higher inci-
dence of loss among those with CD4 ≤ 50 cells/mm3, while
not statistically significant unless restricted to those with
biopsy-proven diagnosis, does suggest that those who were
lost became lost because of death. Therefore, the nominal
estimate of survival we observed using available data is
likely a substantial overestimate. Without ascertaining the
outcomes of those who are lost, we will never understand
true survival after a diagnosis of KS in sub-Saharan Africa.
A limitation of this work is that many of the KS diagnoses
are based on clinical suspicion only. The high frequency of
clinical diagnosis of KS has been documented by others
[35] and is largely due to the limited biopsy infrastruc-
ture in sub-Saharan Africa [36]. Work from East Africa
has shown that there are many conditions that can
clinically mimic KS [37]; it is possible that our study
population, therefore, includes patients with conditions
other than KS. Because we suspect that many more
clinical mimickers of KS have more favorable (as op-
posed to less favorable) prognosis compared to true KS,
we again believe that our nominal estimate of survival
is an overestimate of truth. In addition, due to atypically
rigorous tracking of the lost at one of our sites (Light-
house Clinic in Malawi), we may actually underestimate
the proportion of lost as it compares to a general African
clinic population. Finally, although not a threat to the in-
ternal validity of the overall findings, the sites contributed
sizably different numbers of KS cases, which is in a large
part a reflection of underlying differences in KS epi-
demiology across sub-Saharan Africa.
Conclusions
In summary, this work demonstrates on a large scale the
challenges of accurately estimating cancer survival in
sub-Saharan Africa. This issue is gaining significance as
interventions (such as chemotherapy for KS) become
more readily available, such that monitoring survival over
time is increasingly important. Until we either generally
strengthen data systems or implement cancer-specific en-
hancements to derive more accurate survival estimates
(e.g., tracking of the lost patients with cancer in the com-
munity) in the region, insights from cancer epidemiology
will be severely limited. Strengthening data systems across
this entire region may not be possible in the short term,
but sentinel regional sites could be selected for enhanced
monitoring and tracking of the lost. Additionally, the re-
cent expanding efforts in cancer registries in sub-Saharan
Africa [38–40] will need to closely address the issue of loss
to follow-up in order to truly provide added value.
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